A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS (clinicaltrials.gov) - Oct 17, 2026 - P1 | N=30 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Dermatology • Hidradenitis Suppurativa • Immunology
|